STOK vs. GHRS, OLMA, CALT, ZYME, PHAT, PHAR, LYEL, ORIC, IGMS, and SLN
Should you be buying Stoke Therapeutics stock or one of its competitors? The main competitors of Stoke Therapeutics include GH Research (GHRS), Olema Pharmaceuticals (OLMA), Calliditas Therapeutics AB (publ) (CALT), Zymeworks (ZYME), Phathom Pharmaceuticals (PHAT), Pharming Group (PHAR), Lyell Immunopharma (LYEL), ORIC Pharmaceuticals (ORIC), IGM Biosciences (IGMS), and Silence Therapeutics (SLN). These companies are all part of the "pharmaceutical preparations" industry.
Stoke Therapeutics (NASDAQ:STOK) and GH Research (NASDAQ:GHRS) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their community ranking, institutional ownership, valuation, analyst recommendations, media sentiment, earnings, profitability, risk and dividends.
Stoke Therapeutics received 81 more outperform votes than GH Research when rated by MarketBeat users. Likewise, 72.99% of users gave Stoke Therapeutics an outperform vote while only 67.86% of users gave GH Research an outperform vote.
GH Research's return on equity of -14.56% beat Stoke Therapeutics' return on equity.
56.9% of GH Research shares are owned by institutional investors. 11.3% of Stoke Therapeutics shares are owned by insiders. Comparatively, 41.6% of GH Research shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
In the previous week, Stoke Therapeutics had 11 more articles in the media than GH Research. MarketBeat recorded 18 mentions for Stoke Therapeutics and 7 mentions for GH Research. GH Research's average media sentiment score of 0.62 beat Stoke Therapeutics' score of 0.14 indicating that GH Research is being referred to more favorably in the news media.
Stoke Therapeutics has a beta of 0.82, suggesting that its stock price is 18% less volatile than the S&P 500. Comparatively, GH Research has a beta of 0.8, suggesting that its stock price is 20% less volatile than the S&P 500.
GH Research has lower revenue, but higher earnings than Stoke Therapeutics. GH Research is trading at a lower price-to-earnings ratio than Stoke Therapeutics, indicating that it is currently the more affordable of the two stocks.
Stoke Therapeutics currently has a consensus price target of $20.57, suggesting a potential upside of 46.62%. GH Research has a consensus price target of $36.67, suggesting a potential upside of 188.03%. Given GH Research's stronger consensus rating and higher probable upside, analysts clearly believe GH Research is more favorable than Stoke Therapeutics.
Summary
GH Research beats Stoke Therapeutics on 9 of the 16 factors compared between the two stocks.
Get Stoke Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for STOK and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding STOK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Stoke Therapeutics Competitors List
Related Companies and Tools
